Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: MicroRNA-155 (miR-155) is an oncogenic microRNA, which is upregulated in many human cancers including colorectal cancer (CRC). Overexpression of miR-155 has been found to regulate several cancer-related pathways, and therefore, targeting miR-155 may be an effective strategy for cancer therapy. However, effective and safe delivery of anti-miR-155 to tumors remains challenging for the clinical applications of anti-miR-155-based therapeutics. METHODS: In this study, we explored the expression of miR-155 and the transcription factor nuclear factor kappa B (NF-κB) in CRC tissues and cell lines, and the possible relationship between miR-155 and NF-κB. We further report on anti-miR-155-loaded mesoporous silica nanoparticles (MSNs) modified with polymerized dopamine (PDA) and AS1411 aptamer (MSNs-anti-miR-155@PDA-Apt) for the targeted treatment of CRC. RESULTS: Results showed that miR-155 is overexpressed in CRC tissues and cell lines, and there is a positive feedback loop between NF-κB and miR-155. Compared to the control groups, MSNs-anti-miR-155@PDA-Apt could efficiently downregulate miR-155 expression in SW480 cells and achieve significantly high targeting efficiency and enhanced therapeutic effects in both in vivo and in vitro experiments. Furthermore, inhibition of miR-155 by MSNs-anti-miR-155@PDA-Apt can enhance the sensitivity of SW480 to 5-fluorouracil chemotherapy. CONCLUSION: Thus, our results suggested that MSNs-anti-miR-155@PDA-Apt is a promising nanoformulation for CRC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: small RNAs with a big role in gene regulation
He, L., & Hannon, G. J. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1379 · Cited by 7,118
Self-citationsiRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081 · cited 1×
“Unlike short interfering RNAs (siRNAs) with one specific target mRNA, miRNAs can achieve gene-silencing effect by regulating multiple mRNAs, which make them efficient tools for the treatment of complex multigenic diseases including cancers.(4) Restoring miRNA function with miRNA mimics and inhibiting the function of a…”
Self-citationJiang, S., Zhang, H.-W., Lu, M.-H., He, X.-H., Li, Y., Gu, H., Liu, M.-F., & Wang, E.-D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4250 · Cited by 679
Self-citationDevelopment of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
Polydopamine-Based Simple and Versatile Surface Modification of Polymeric Nano Drug Carriers
Park, J., Brust, T. F., Lee, H. J., Lee, S. C., Watts, V. J., & Yeo, Y. (2014) · ACS Nano · doi:10.1021/nn405809c · Cited by 407 · cited 3×
“Then, the obtained MSNs-anti-miR-155@ PDA were collected by centrifugation and washed with deionized water to remove the unpolymerized dopamine.(30)”
InfluentialmiR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Bayraktar, R., & Van Roosbroeck, K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9724-7 · Cited by 216
The multiple roles of microRNA-155 in oncogenesis
Higgs, G., & Slack, F. (2013) · Journal of Clinical Bioinformatics · doi:10.1186/2043-9113-3-17 · Cited by 137 · cited 1×
“MiR-155, functioning as an OncomiR, has multiple targets in human cancers.(39) Previous studies show that miR-155 can enhance NF-κB activity by targeting its negative regulators.”
NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia
Gerloff, D., Grundler, R., Wurm, A. A., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Madan, V, Müller-Tidow, C., Duyster, J., Tenen, D. G., et al. (2015) · Leukemia · doi:10.1038/leu.2014.231 · Cited by 135 · cited 1×
“Meanwhile, other studies show that miR-155 was found to be upregulated by NF-κB.(42,43) Therefore, there may be a positive feedback loop between NF-κB and miR-155.”
Cited by
Recent Advances in miRNA Delivery Systems
Dasgupta, I., & Chatterjee, A. (2021) · Methods and Protocols · doi:10.3390/mps4010010 · Cited by 307
Therapeutic applications of AS1411 aptamer, an update review
Yazdian-Robati, R., Bayat, P., Oroojalian, F., Zargari, M., Ramezani, M., Taghdisi, S. M., & Abnous, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.118 · Cited by 288
“High targeting efficiency and improved therapeutic performance both in vivo and in vitro are the main features of this project [70].”
BackgroundMirzaei, S., Zarrabi, A., Hashemi, F., Zabolian, A., Saleki, H., Ranjbar, A., Seyed Saleh, S. H., Bagherian, M., Sharifzadeh, S. O., Hushmandi, K., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.025 · Cited by 224
miR-155: An Important Role in Inflammation Response
Hu, J., Huang, S., Liu, X., Zhang, Y., Wei, S., & Hu, X. (2022) · Journal of Immunology Research · doi:10.1155/2022/7437281 · Cited by 171
“miR-155 was an important biomarker for understanding the molecular mechanisms and etiology of various diseases [13, 14].”
Self-citationMomin, M. Y., Gaddam, R. R., Kravitz, M., Gupta, A., & Vikram, A. (2021) · Cells · doi:10.3390/cells10113097 · Cited by 107
“Mesoporous silica nanoparticles efficiently delivered the miR-155 inhibitor to colorectal cancer cells in vitro and in vivo [72].”
Background
Metadata
- Authors
- Li, Y., Duo, Y., Bi, J., Zeng, X., Mei, L., Bao, S., He, L., Shan, A., Zhang, Y., & Yu, X.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-03
- Volume
- Volume 13
- Pages
- 1241-1256
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2790048064
- Cited by
- 124
- References
- 8
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. https://app.cochat.ai/papers/10.2147/ijn.s158290
- The paper
- Li, Y., Duo, Y., Bi, J., Zeng, X., Mei, L., Bao, S., He, L., Shan, A., Zhang, Y., & Yu, X. (2018). Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s158290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.